901 ADDING SIMEPREVIR (TMC435) TO PEGYLATED INTERFERON/ RIBAVIRIN DOES NOT INCREASE PATIENT REPORTED FATIGUE IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV INFECTION: RESULTS FROM THE ASPIRE TRIAL
2013; Elsevier BV; Volume: 58; Linguagem: Inglês
10.1016/s0168-8278(13)60903-4
ISSN1600-0641
AutoresJohn D. Scott, Kathleen Rosa, Stefan Zeuzem, Maria Beumont‐Mauviel, Marc Peeters, Karin Cerri, Min Fu, L. Gilles,
Tópico(s)Blood groups and transfusion
Resumo901 ADDING SIMEPREVIR (TMC435) TO PEGYLATED INTERFERON/ RIBAVIRIN DOES NOT INCREASE PATIENT REPORTED FATIGUE IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV INFECTION: RESULTS FROM THE ASPIRE TRIAL J. Scott, K. Rosa, S. Zeuzem, M. Beumont-Mauviel, M. Peeters, K. Cerri, M. Fu, L. Gilles. Janssen Global Services, High Wycombe, UK; University of North Carolina at Wilmington, Wilmington, DE, USA; University Hospital, JW Goethe University, Frankfurt, Germany; Janssen Research and Development, Janssen Pharmaceutica NV, Janssen Pharmaceutica NV, Beerse, Belgium; Janssen Research and Development US, Spring House, PA, USA E-mail: jscott51@its.jnj.com
Referência(s)